سعر بريفاكسينال 2.5مجم 30 قرص 2022

Apixaban 2.5 mg film-coated tablets (direct factor Xa inhibitor), box of 30 tablets, by DBK Pharma, Egypt.

• Reduce the risk of stroke and systemic embolism in adults with nonvalvular atrial fibrillationPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Prophylaxis of deep vein thrombosis after hip or knee replacement surgeryPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Treatment of DVT and PE and reduction in the risk of recurrent DVT and PE after initial therapyPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (>1%) in adults are related to bleeding.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Active pathological bleeding.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Severe hypersensitivity reaction to apixaban (e.g. anaphylaxis).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Premature discontinuation increases the risk of thrombotic events.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Can cause serious, potentially fatal bleeding; a reversal agent for anti-factor Xa activity is available.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Not recommended with prosthetic heart valves or triple-positive antiphospholipid syndrome; spinal/epidural hematoma risk.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Combined P-gp and strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir)Increase apixaban levels; at 2.5 mg twice daily avoid coadministration.DailyMed (U.S. National Library of Medicine)
• Combined P-gp and strong CYP3A4 inducers (e.g. rifampin, carbamazepine, phenytoin, St John's wort)Decrease apixaban exposure; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
• Antiplatelets, other anticoagulants, heparin, fibrinolytics, NSAIDs, SSRIs/SNRIsIncrease bleeding risk.DailyMed (U.S. National Library of Medicine)

• Limited data are insufficient to inform drug-associated risks; treatment may increase the risk of bleeding during pregnancy and delivery.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No human milk data; apixaban is present in rat milk; breastfeeding is not recommended during treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Apixaban: Selective, reversible inhibitor of free and clot-bound factor Xa and prothrombinase activity, decreasing thrombin generation; no direct effect on platelet aggregation (US label).